Becton Dickinson (BDX) Buy, Sell or Hold

Becton Dickinson (BDX)

143.96

-0.02 (0.01%)

as of Jun 18, 2026, 7:59:59 pm Market Open.

109 watching

BUY

A good opportunity. Covid has led to deferral of elective surgeries, so revenues are suffering and the market didn't like this. Vaccine testing will help them quite a bit to monetize their testing technology. Reasonable opportunity. Wouldn't be shy to buy at these levels.

BUY

Allan Tong’s Discover Picks The pandemic helped BDX, since most of its products are disposable. Then again, during the spring lockdown, surgeries were cancelled across the board, so use of BDX's products nearly halted. Its chart this year has been rocky, though earlier this month, the stock returned to previous highs above $280 while it has met or narrowly beat its EPS in the past four quarters. BDX continues to be profitable at a margin of 7.13% and a 15.41% five-year average revenue growth. Forward PE stands at 20.44x and it pays a dividend of 1.2%. Read BDX, BSX, ISRG and Stryker Stock: Top 4 Medical Supply Stocks for our full analysis.

BUY

One of the better US healthcare companies, making needles and test tubes. BDX has done very well in recent years though flat during COVID, so he expects a catch-up. No reason to be afraid of this. It's a solid stock that will grow 3-5% annually.

PAST TOP PICK

(A Top Pick Jun 24/19, Up 12%) The only company that can manufacture disposable, consumable medical products, especially syringes. They benefit from the pandemic and will benefit from the aging population.

PAST TOP PICK

(A Top Pick Jun 24/19, Down 6%) Hospitals were kind of closed across North America. These guys were a supplier for hospitals. If there are no surgeries then there is less demand for their one time use products. A billion plus doses of a vaccine will require their syringes.

TOP PICK

Most of their medical devices are disposable, and now they have a new COVID test. So, 90% of revenues are recurring and will only increase by 14% in the coming 12 months and double-digits in years to follow. They are incredibly well-positioned and enjoy consistent demand. (Analysts’ price target is $268.53)

COMMENT

Investing in healthcare is hard. He holds BDX which he sees it as the shopping mall of healthcare products. He used to own ZBH but they suffered from recalls. He would probably stick to one of the three since he believes they are the best run companies in healthcare.

SELL

A big miss in earnings and sold off. Move on. Maybe it finds its footing in a few days.

HOLD

The stock took a hit but he would hold. Their pump software is not working and they had to withdraw it from the market. Yesterday, they reduced their forward earnings $12-$12.10. He wouldn't buy it today, but if it falls to 15x earnings, he would pull the trigger. They started with needles and they have existed for over 100 years. They continue to pay down their debt and their dividends are rising at around 7%. You can invest in it and let the company do what it does.

BUY

Good time to get into healthcare and which stock? The Canadian Tire of healthcare supplies. Medtronic is also good.

BUY

A very solid business, making most of the syringes etc. used in hospitals world-wide. This business is growing. They sell at 25+ times earnings because of the quality of the business. (Analysts’ price target is $282.00)

PAST TOP PICK

(A Top Pick Nov 02/18, Up 11%) Medical supplies giant. They've been around for 100 year. Syringes are their big product. They made a large acquisition but are paying down debt. They continue their investment grade credit. The medical supply business has done better than pharmaceuticals.

BUY ON WEAKNESS

Favorable time to own health stocks in front of the US elections. A very solid investment you can certainly sleep at night with it. Would be a bit cautious on the purchase price and buy it on a downturn.

TOP PICK

Just because the population is aging, doesn't mean you'll benefit from it. BDX is in medical supplies, not drugs, supplying hospitals. They've pulled back a little, because a product is under FDA review. They have a good record of raising their dividend, and they have a long runway of opportunities ahead. (Analysts’ price target is $259.67)

BUY

One of the solid players in the sector. The Health Care sector has been disrupted before elections as politicians take it out on the companies in the sector. Great time to buy it and hold it riding the volatility until the election.

Showing 16 to 30 of 83 entries

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Most Recent Experts

Stockchase Insights

5i Research

Brian Acker, CA

Acker Finley Inc.

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

David Burrows

Barometer Capital Management

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Becton Dickinson (BDX)